Welcome to our dedicated page for Elite Pharmaceuticals news (Ticker: ELTP), a resource for investors and traders seeking the latest updates and insights on Elite Pharmaceuticals stock.
Elite Pharmaceuticals, Inc. develops, manufactures, and distributes niche generic pharmaceutical products, with product lines focused on immediate-release and controlled-release solid oral dose products. Company news commonly covers FDA approvals for abbreviated new drug applications, commercial launches under the Elite Laboratories label, and licensed distribution relationships with third-party pharmaceutical marketing organizations.
Recurring updates also include quarterly financial results, conference-call announcements, and operating commentary tied to generic product sales. Recent company developments have included methadone hydrochloride tablets, ropinirole extended-release tablets, lisdexamfetamine products, and naltrexone products within Elite's generic drug portfolio.
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) reported a strong performance for the third quarter of fiscal year 2022, ended December 31, 2021. Consolidated revenues reached $9.0 million, up 48% year-over-year, driven by increased sales of Amphetamine IR Tablets and ER Capsules. The company also posted an operating profit of $1.8 million, an increase of $0.8 million compared to the prior year, and net income of $2.3 million. A conference call is scheduled for February 15 at 11:30 AM EST to discuss these results and recent developments.
Elite Pharmaceuticals (OTC PINK:ELTP) will announce its third quarter financial results for the fiscal year 2022 on February 14, 2022. Following the release, management will conduct a live conference call on February 15, 2022, at 11:30 AM EST to review financials and operational updates. Shareholders are encouraged to submit questions prior to the call. Elite Pharmaceuticals specializes in developing niche generic products and operates a cGMP facility in Northvale, NJ.
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) reported second quarter fiscal year 2022 financial results for the period ending September 30, 2021. The company achieved revenues of $8.6 million, reflecting a 16% increase from the previous year, driven by strong sales of Amphetamine IR Tablets and ER Capsules. Operating profits rose to $1.4 million, and net income was $1.8 million. A conference call regarding these results is scheduled for November 16, 2021, at 11:30 AM EST.
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) will release its second quarter financial results for the fiscal year 2022 on November 15, 2021. A live conference call is scheduled for November 16 at 11:30 AM EST, where management will discuss financial and operating results, alongside a business update. Stakeholders are encouraged to submit questions before the call. Elite Pharmaceuticals focuses on developing niche generic products and operates a cGMP facility in Northvale, NJ. For more details, visit www.elitepharma.com.
Elite Pharmaceuticals (OTCQB:ELTP) reported a 6% decline in total revenues for Q1 FY 2022, reaching $7.1 million compared to $7.5 million in the same period last year. This decrease is attributed to the timing of sales of Amphetamine products. However, the company reported stronger margins leading to operating profits of $1.0 million, an increase of $0.2 million year-over-year, and net income of $2.4 million. A conference call is scheduled for August 17, 2021, to discuss the results further.
Elite Pharmaceuticals (OTCQB:ELTP) announced the release of its first quarter financial results for fiscal year 2022 on August 16, 2021. A live conference call to discuss these results and provide a business update is scheduled for August 17, 2021, at 11:30 AM EDT. Stakeholders are encouraged to submit questions ahead of the call. The company specializes in developing niche generic pharmaceutical products and operates a cGMP and DEA registered facility in Northvale, NJ.
Elite Pharmaceuticals reported a significant increase in fiscal year 2021 revenues, totaling $25.4 million, up 41% from the prior year. The revenue growth is primarily driven by sales of generic Adderall and Isradipine products. Operating profits rose to $2.1 million, a substantial improvement of $4.3 million year-over-year, with net income reported at $5.1 million. A conference call is scheduled for June 15, 2021, to discuss these results and future business developments.
Elite Pharmaceuticals (OTCBB:ELTP) will release its 2021 year-end financial results on June 14, 2021. A live conference call is scheduled for June 15 at 11:30 AM EDT to discuss the financials and provide a business update. Stockholders are encouraged to submit questions before the call. The financial statements will be available in the 10-K report. Elite develops and manufactures niche generic pharmaceuticals and operates a GMP facility in Northvale, NJ. This announcement sets the stage for potentially significant financial insights for the company.
Elite Pharmaceuticals announced a partnership with Prasco, LLC for the exclusive distribution of its generic Loxapine capsules. This agreement allows Prasco to manage sales and marketing in the US, while Elite will handle manufacturing. Loxapine, indicated for treating schizophrenia, is currently on the FDA drug shortage list, indicating a critical need for its availability. Prasco's infrastructure aims to ensure nationwide access, improving supply in the healthcare market.
Elite Pharmaceuticals has announced the appointment of Marc Bregman, CPA, as the new Chief Financial Officer, effective May 17, 2021. With over 27 years of experience, Bregman has held significant financial roles at various companies, enhancing his expertise in financial accounting and compliance. President and CEO Nasrat Hakim expressed confidence that Bregman's leadership will be pivotal for Elite's growth. Elite Pharmaceuticals specializes in developing niche generic products and operates a cGMP facility in Northvale, NJ.